The effects of 5-HT1A, 5-HT1B and 5-HT1D receptor agonists on trigeminal nociceptive neurotransmission in anaesthetized rats

被引：45

作者：

Cumberbatch, MJ ^{[1
]}

Hill, RG ^{[1
]}

Hargreaves, RJ ^{[1
]}

机构：

[1] Merck Sharp & Dohme Res Labs, Neurosci Res Ctr, Harlow CM20 2QR, Essex, England

来源：

EUROPEAN JOURNAL OF PHARMACOLOGY | 1998年 / 362卷 / 01期

关键词：

zolmitriptan; migraine; 5-HT1B/1D receptor; 5-HT1A receptor; CP-93,129;

D O I：

10.1016/S0014-2999(98)00764-X

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Pre-clinical studies have suggested that one mechanism of antimigraine action of the 'triptan' 5-HT1B/1D receptor agonists may be through inhibition of central nociceptive transmission in the trigeminal dorsal horn. In anaesthetized rats, the 5-HT1B/1D receptor agonist, zolmitriptan (up to 3 mg kg(-1), i.v.), inhibited the action potential discharge of single trigeminal neurones to noxious electrical stimulation of the middle meningeal artery. In contrast, the selective 5-HT1B receptor agonist, CP-93,129 (3-(1,2,5,6-tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one), and the 5-HT1B receptor selective agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT) had no effect in this assay at up to 3 mg kg(-1), i.v.. Brain penetrant, triptan 5-HT1B/1D receptor agonists may therefore mediate their central trigeminal anti-nociceptive action in the rat via 5-HT1D, but not 5-HT1B or 5-HT1A, receptors. (C) 1998 Elsevier Science B.V. All rights reserved.

引用

页码：43 / 46

页数：4

共 19 条

[11] Differential distribution of 5HT1D- and 5HT1B-immunoreactivity within the human trigemino-cerebrovascular system:: Implications for the discovery of new antimigraine drugs [J].

Longmore, J ;

Shaw, D ;

Smith, D ;

Hopkins, R ;

McAllister, G ;

Pickard, JD ;

Sirinathsinghji, DJS ;

Butler, AJ ;

Hill, RG .

CEPHALALGIA, 1997, 17 (08) :833-842

[12] 3-(1,2,5,6-TETRAHYDROPYRID-4-YL)PYRROLO[3,2-B]PYRID-5-ONE - A POTENT AND SELECTIVE SEROTONIN (5-HT1B) AGONIST AND ROTATIONALLY RESTRICTED PHENOLIC ANALOG OF 5-METHOXY-3-(1,2,5,6-TETRAHYDROPYRID-4-YL)INDOLE [J].

MACOR, JE ;

BURKHART, CA ;

HEYM, JH ;

IVES, JL ;

LEBEL, LA ;

NEWMAN, ME ;

NIELSEN, JA ;

RYAN, K ;

SCHULZ, DW ;

TORGERSEN, LK ;

KOE, BK .

JOURNAL OF MEDICINAL CHEMISTRY, 1990, 33 (08) :2087-2093

[13] Pre-clinical pharmacology of zolmitriptan (Zomig(TM); formerly 311C90), a centrally and peripherally acting 5HT(1B)/(1D) agonist for migraine [J].

Martin, GR .

CEPHALALGIA, 1997, 17 :4-14

[14] NEUROGENIC VERSUS VASCULAR MECHANISMS OF SUMATRIPTAN AND ERGOT ALKALOIDS IN MIGRAINE [J].

MOSKOWITZ, MA .

TRENDS IN PHARMACOLOGICAL SCIENCES, 1992, 13 (08) :307-311

[15] Differential effects of 5-HT1B/1D receptor agonists on neurogenic dural plasma extravasation and vasodilation in anaesthetized rats [J].

Shepherd, SL ;

Williamson, DJ ;

Beer, MS ;

Hill, RG ;

Hargreaves, RJ .

NEUROPHARMACOLOGY, 1997, 36 (4-5) :525-533

[16] Microiontophoretic application of serotonin (5HT)1B/1D agonists inhibits trigeminal cell firing in the cat [J].

Storer, RJ ;

Goadsby, PJ .

BRAIN, 1997, 120 :2171-2177

[17] Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets [J].

Tattersall, FD ;

Rycroft, W ;

Francis, B ;

Pearce, D ;

Merchant, K ;

MacLeod, AM ;

Ladduwahetty, T ;

Keown, L ;

Swain, C ;

Baker, R ;

Cascieri, M ;

Ber, E ;

Metzger, J ;

MacIntyre, DE ;

Hill, RG ;

Hargreaves, RJ .

NEUROPHARMACOLOGY, 1996, 35 (08) :1121-1129

[18] THE CONCEPT OF SELECTIVITY IN 5-HT RECEPTOR RESEARCH [J].

VANWIJNGAARDEN, I ;

TULP, MTM ;

SOUDIJN, W .

EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1990, 188 (06) :301-312

[19] Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat - Intravital microscope studies [J].

Williamson, DJ ;

Hargreaves, RJ ;

Hill, RG ;

Shepheard, SL .

CEPHALALGIA, 1997, 17 (04) :525-531

← 1 2 →